Recombinant Humanized Anti-MERS-CoV Antibody (m336) (CAT#: HPAB-2420LY)

Figure 1 Viral titers in rabbit lungs following intravenous prophylaxis with neutralizing monoclonal antibody.

Rabbits received Middle East respiratory syndrome coronavirus (MERS-CoV)-specific human monoclonal antibody (hmAb) m336 or irrelevant control hmAb m102.4 intravenously 24 hours before intranasal infection with 105 50% tissue culture infective doses (TCID50) of EMC/2012. A, Lungs were collected on days 1 and 3 after infection, and viral titers were quantified by quantitative real time polymerase chain reaction analysis. **P <.005 and ***P <.001 by 1-way analysis of variance, with the Tukey multiple comparisons test. Abbreviation: eq, equivalents.

Houser, K. V., Gretebeck, L., Ying, T., Wang, Y., Vogel, L., Lamirande, E. W.,... & Subbarao, K. (2016). Prophylaxis with a Middle East respiratory syndrome coronavirus (MERS-CoV)-specific human monoclonal antibody protects rabbits from MERS-CoV infection. The Journal of infectious diseases, 213(10), 1557-1561.

Figure 2 Viral titers in rabbit lungs following intranasal prophylaxis with neutralizing monoclonal antibody.

Rabbits received Middle East respiratory syndrome coronavirus (MERS-CoV)-specific human monoclonal antibody (hmAb) m336 or irrelevant control hmAb m102.4 intranasally 24 hours before intranasal infection with 105 50% tissue culture infective doses (TCID50) of EMC/2012. A, Lungs were collected on days 1 and 3 after infection, and viral titers were quantified by quantitative real time polymerase chain reaction analysis. **P <.005 and ***P <.001 by 1-way analysis of variance, with the Tukey multiple comparisons test. Abbreviation: eq, equivalents.

Houser, K. V., Gretebeck, L., Ying, T., Wang, Y., Vogel, L., Lamirande, E. W.,... & Subbarao, K. (2016). Prophylaxis with a Middle East respiratory syndrome coronavirus (MERS-CoV)-specific human monoclonal antibody protects rabbits from MERS-CoV infection. The Journal of infectious diseases, 213(10), 1557-1561.

Figure 3 Strong synergism of HR2P-M2 combined with m336 against MERS-CoV pseudovirus infection.

The effective concentrations for inhibiting MERS-CoV pseudovirus infection are plotted in two curves. The blue curves represent inhibitors used alone, and the red curves represent each inhibitor used in combination. The width between two curves represents the fold of enhancement between an inhibitor used alone and in combination.

Wang, C., Hua, C., Xia, S., Li, W., Lu, L., & Jiang, S. (2019). Combining a fusion inhibitory peptide targeting the MERS-CoV S2 protein HR1 domain and a neutralizing antibody specific for the S1 protein receptor-binding domain (RBD) showed potent synergism against pseudotyped MERS-CoV with or without mutations in RBD. Viruses, 11(1), 31.

Figure 4 Strong synergism resulting from the HR2P-M2/m336 combination against MERS-CoV S protein-mediated cell–cell fusion.

Wang, C., Hua, C., Xia, S., Li, W., Lu, L., & Jiang, S. (2019). Combining a fusion inhibitory peptide targeting the MERS-CoV S2 protein HR1 domain and a neutralizing antibody specific for the S1 protein receptor-binding domain (RBD) showed potent synergism against pseudotyped MERS-CoV with or without mutations in RBD. Viruses, 11(1), 31.

Figure 5 MERS-CoV pseudovirus inhibitory activity as determined from sera of BALB/c mice treated with m336 (0.01 mg) alone, HR2P-M2 (1 mg) alone, or m336 (0.01 mg)/HR2P-M2 (1 mg) in combination.

Data are presented as means ± SD. **, and *** represent p < 0.01, and p < 0.001, respectively.

Wang, C., Hua, C., Xia, S., Li, W., Lu, L., & Jiang, S. (2019). Combining a fusion inhibitory peptide targeting the MERS-CoV S2 protein HR1 domain and a neutralizing antibody specific for the S1 protein receptor-binding domain (RBD) showed potent synergism against pseudotyped MERS-CoV with or without mutations in RBD. Viruses, 11(1), 31.

Figure 6 Binding of IgG1s m336, m336-gH, m336-gL-FR, m336-gL and a negative control IgG1 m102.4 to MERS-CoV S1 protein measured by ELISA.

Ying, T., Prabakaran, P., Du, L., Shi, W., Feng, Y., Wang, Y.,... & Zhou, T. (2015). Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nature communications, 6(1), 1-10.

Figure 7 Neutralization of viruses pseudotyped with the MERS-CoV S glycoprotein.

Ying, T., Prabakaran, P., Du, L., Shi, W., Feng, Y., Wang, Y.,... & Zhou, T. (2015). Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nature communications, 6(1), 1-10.

Figure 8 Binding of Fab m336 allele-specific mutants (F54L and K73E) to MERS-CoV S1 protein measured by ELISA.

Ying, T., Prabakaran, P., Du, L., Shi, W., Feng, Y., Wang, Y.,... & Zhou, T. (2015). Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nature communications, 6(1), 1-10.